Danish Study Finds GLP-1 Drugs Reduce Long-Term Sick Leave by 17%
A study based on Danish data found that patients taking GLP-1 drugs experienced 17% fewer long-term work absences compared to those not on the medications. The research examined workplace absenteeism patterns among GLP-1 users. The findings suggest potential broader economic benefits beyond direct health outcomes. For Medicaid programs covering GLP-1s for weight management or diabetes, this data may inform cost-benefit analyses around coverage decisions, though workforce participation effects in Medicaid populations may differ from the Danish workforce studied.
Provides economic data that state Medicaid agencies and health plans may reference when evaluating coverage policies for high-cost GLP-1 medications, though direct applicability to U.S. Medicaid populations requires further analysis.
Pharmacy · Managed Care
You might also like